Scandinavian journal of clinical and laboratory investigation · 2014
Quantification of valproic acid in dried blood spots.
СтатьяПоддержка исследования: вне правительства СШАВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pohanka Anton, Mahindi Margarita, Masquelier Michèle, Gustafsson Lars L, Beck Olof
Аннотация
BACKGROUND: Therapeutic drug monitoring (TDM) of the antiepileptic drug valproic acid (VPA) is recommended in patients with multiple drug therapy or with concomitant disabilities to ensure treatment efficacy and avoid adverse reactions in both adults and children. The use of sampling techniques compatible with home sampling, such as dried blood spot sampling could potentially facilitate this for patients. AIM. To assess the usefulness of a bioanalytical method for quantification of VPA in dried blood spots.
MATERIALS AND METHODS: Quantification was based on liquid chromatography-mass spectrometry (LC-MS), both for the DBS method and the plasma-based reference method.
RESULTS: The method was validated in the range 10-1200 μmol/L. Total imprecision ranged from 4.9-8.9 (%CV) and accuracy was within ± 14%.
CONCLUSION: The validated method has potential for evaluation in therapeutic drug monitoring in combination with home sampling of DBS. The impact of spot size can be controlled through acceptance criteria and hematocrit in the range 30-60% can be accepted in sampling. Comparison of VPA levels between plasma and whole blood cannot be done without considering the blood-plasma ratio.
MATERIALS AND METHODS: Quantification was based on liquid chromatography-mass spectrometry (LC-MS), both for the DBS method and the plasma-based reference method.
RESULTS: The method was validated in the range 10-1200 μmol/L. Total imprecision ranged from 4.9-8.9 (%CV) and accuracy was within ± 14%.
CONCLUSION: The validated method has potential for evaluation in therapeutic drug monitoring in combination with home sampling of DBS. The impact of spot size can be controlled through acceptance criteria and hematocrit in the range 30-60% can be accepted in sampling. Comparison of VPA levels between plasma and whole blood cannot be done without considering the blood-plasma ratio.